Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
The Journal of Adolescent Health : Official Publication of the Society for Adolescent Medicine|January 24, 2012
Four-year follow-up of the immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine when administered to adolescent girls aged 10-14 yearsTino F Schwarz, Li-Min Huang, Doris Maribel Rivera Medina, et al.
Vaccine|November 3, 2009
RotaTeq, a pentavalent rotavirus vaccine: efficacy and safety among infants in EuropeTimo Vesikari, Robbin Itzler, Aino Karvonen, et al.
European Journal of Pediatrics|February 12, 2010
Safety, immunogenicity and immediate pain of intramuscular versus subcutaneous administration of a measles-mumps-rubella-varicella vaccine to children aged 11-21 monthsMarkus Knuf, Fred Zepp, Claudius U Meyer, et al.
Human Vaccines & Immunotherapeutics|March 1, 2014
Immune response to the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose or 3-dose schedule up to 4 years after vaccination: results from a randomized studyBarbara Romanowski, Tino F Schwarz, Linda M Ferguson, et al.
The Journal of Adolescent Health : Official Publication of the Society for Adolescent Medicine|February 2, 2010
Immunogenicity and safety of human papillomavirus-16/18 AS04-adjuvanted cervical cancer vaccine coadministered with combined diphtheria-tetanus-acellular pertussis-inactivated poliovirus vaccine to girls and young womenJosé Garcia-Sicilia, Tino F Schwarz, Alfonso Carmona, et al.
Vaccine|July 2, 2018
Immunogenicity and safety of the quadrivalent meningococcal vaccine MenACWY-TT co-administered with a combined diphtheria-tetanus-acellular pertussis vaccine versus their separate administration in adolescents and young adults: A phase III, randomized studyLuis Rivera, Tino F Schwarz, Kyung-Hyo Kim, et al.
Vaccine|August 1, 2012
A non-adjuvanted whole-virus H1N1 pandemic vaccine is well tolerated and highly immunogenic in children and adolescents and induces substantial immunological memoryAlexandra Loew-Baselli, Borislava G Pavlova, Sandor Fritsch, et al.
BMC Pediatrics|February 9, 2019
Safety and immunogenicity of a varicella vaccine without human serum albumin (HSA) versus a HSA-containing formulation administered in the second year of life: a phase III, double-blind, randomized studySaul N Faust, Maguelone Le Roy, Chitsanu Pancharoen, et al.
The Journal of Infectious Diseases|February 5, 2019
Long-term Cross-reactivity Against Nonvaccine Human Papillomavirus Types 31 and 45 After 2- or 3-Dose Schedules of the AS04-Adjuvanted Human HPV-16/18 VaccineNicolas Folschweiller, Ulrich Behre, Marc Dionne, et al.
BMC Infectious Diseases|April 20, 2018
Assessment of an optimized manufacturing process for inactivated quadrivalent influenza vaccine: a phase III, randomized, double-blind, safety and immunogenicity study in children and adultsCarine Claeys, Mamadou Drame, José García-Sicilia, et al.
Pageof 2